SCHEMBL1381858

SCHEMBL1381858

Cc1cc(NS(=O)(=O)c2ccccc2)nc(C)n1

nearest known ligand 0.73

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.73
AGO2 Q9UKV8 1/20 0.73
ALDH1A1 P00352 6/20 0.69
KDM4E B2RXH2 3/20 0.69
LMNA P02545 1/20 0.69
TSHR P16473 2/20 0.64
HSD11B1 P28845 1/20 0.62
HPGD P15428 1/20 0.62
HSD17B10 Q99714 1/20 0.62
GAA P10253 1/20 0.61
PKM P14618 1/20 0.61
POLB P06746 2/20 0.59
USP2 O75604 1/20 0.57
SMN1; SMN2 Q16637 2/20 0.56
ALOX15 P16050 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1381435 0.85 HSD11B1 (0.68) PDE4AAGO2ALDH1A1KDM4ELMNA
SCHEMBL11757838 0.84 PDE4A (0.69) PDE4AAGO2ALDH1A1KDM4ELMNA
SCHEMBL1828300 0.84 PDE4A (0.74) PDE4AAGO2ALDH1A1KDM4ELMNA
Sulfisomidine SCHEMBL34791 0.84 PDE4A (1.00) PDE4AAGO2ALDH1A1KDM4ELMNA
Sulfisomidine SCHEMBL284793 0.83 PDE4A (0.97) PDE4AAGO2ALDH1A1KDM4ELMNA
SCHEMBL12010926 0.83 HSD11B1 (0.68) PDE4AAGO2ALDH1A1KDM4ELMNA
SCHEMBL290584 0.80 ALDH1A1 (0.71) PDE4AAGO2ALDH1A1KDM4ELMNA
SCHEMBL5453637 0.80 PDE4A (0.71) PDE4AAGO2ALDH1A1KDM4ELMNA
Sulfamethazine SCHEMBL28086389 0.79 PDE4A (0.87) PDE4AAGO2ALDH1A1KDM4ELMNA
SCHEMBL17682474 0.78 TSHR (0.70) ALDH1A1KDM4ELMNATSHRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4809339-B2 2011-11-09 JP claimed
EP-1763517-B1 PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS HOFFMANN LA ROCHE (CH) 2011-05-11 EP claimed
CN-1972918-B Pyrimidine derivatives HOFFMANN LA ROCHE 2010-10-13 CN claimed
US-7507733-B2 11b-HSD1 inhibitors for the treatment of diabetes HOFFMANN-LA ROCHE INC. (US) 2009-03-24 US claimed
CN-1972918-A Pyrimidine derivatives HOFFMANN LA ROCHE (CH) 2007-05-30 CN claimed
EP-1763517-A2 PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2007-03-21 EP claimed
WO-2006000371-A2 PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2006-01-05 WO claimed
US-20050288308-A1 11B-HSD1 inhibitors for the treatment of diabetes F. HOFFMANN-LA ROCHE AG (CH) 2005-12-29 US claimed
EP-3841233-A1 ELECTROLYTE FOR THE CYANIDE-FREE DEPOSITION OF SILVER Umicore Galvanotechnik GmbH (DE) 2021-06-30 EP disclosed
EP-1763517-B1 PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS HOFFMANN LA ROCHE (CH) 2011-05-11 EP disclosed
CN-1972918-B Pyrimidine derivatives HOFFMANN LA ROCHE 2010-10-13 CN disclosed
US-7507733-B2 11b-HSD1 inhibitors for the treatment of diabetes HOFFMANN-LA ROCHE INC. (US) 2009-03-24 US disclosed
CN-1972918-A Pyrimidine derivatives HOFFMANN LA ROCHE (CH) 2007-05-30 CN disclosed
EP-1763517-A2 PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2007-03-21 EP disclosed
WO-2006000371-A2 PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2006-01-05 WO disclosed
US-20050288308-A1 11B-HSD1 inhibitors for the treatment of diabetes F. HOFFMANN-LA ROCHE AG (CH) 2005-12-29 US disclosed
US-20040110775-A1 Cyclin dependent kinase inhibiting purine derivatives CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2004-06-10 US disclosed
EP-1353922-A1 CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES Cancer Research Technology Limited (GB) 2003-10-22 EP disclosed
WO-2002059125-A1 CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2002-08-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288308-A1 11B-HSD1 inhibitors for the treatment of diabetes HSD11B1, HSD17B1, HSD3B1 PDE4A 432/4885AGO2 4712/4885ALDH1A1 82/4885
US-20040110775-A1 Cyclin dependent kinase inhibiting purine derivatives CCNA1, CDKL1, CCNK PDE4A 3290/4885AGO2 4786/4885ALDH1A1 2396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.